Literature DB >> 25661974

Quality of Life in Acromegaly.

Susan M Webb1, Xavier Badia.   

Abstract

Available disease-specific questionnaires like the Acromegaly Quality of Life questionnaire have confirmed that quality of life (QoL) is impaired in acromegaly, especially in active disease. Successful therapy improves QoL, but it may not normalize completely even after endocrine cure; furthermore, there is not always a correlation between growth hormone (GH) and insulin-like growth factor 1 and subjective health perception of QoL. Appearance is the dimension most affected and has the highest impact on the patient's QoL. Worse QoL is associated with the presence of musculoskeletal pain, headache (if only medical therapy, not surgery, has been provided), having required treatment with radiotherapy, being older, of female gender, with a longer disease duration, coexisting diabetes mellitus, a higher BMI or becoming GH deficient after treatment for acromegaly.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25661974     DOI: 10.1159/000375451

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

Review 1.  Update on quality of life in patients with acromegaly.

Authors:  Iris Crespo; Elena Valassi; Susan M Webb
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy.

Authors:  H Alibas; K Uluc; P Kahraman Koytak; M M Uygur; N Tuncer; T Tanridag; D Gogas Yavuz
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

3.  Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database.

Authors:  Federico Gatto; Gianluca Trifirò; Francesco Lapi; Francesco Cocchiara; Claudia Campana; Carlotta Dell'Aquila; Carmen Ferrajolo; Marica Arvigo; Claudio Cricelli; Massimo Giusti; Diego Ferone
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

4.  Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.

Authors:  Roberto Salvatori; Pietro Maffei; Susan M Webb; Thierry Brue; Jane Loftus; Srinivas Rao Valluri; Roy Gomez; Michael P Wajnrajch; Maria Fleseriu
Journal:  Pituitary       Date:  2022-01-12       Impact factor: 4.107

5.  Quality of Life in Patients with Acromegaly before and after Transsphenoidal Surgical Resection.

Authors:  Jing Gu; Shiyuan Xiang; Min He; Meng Wang; Yanfang Gu; Lingjuan Li; Zhiwen Yin
Journal:  Int J Endocrinol       Date:  2020-08-04       Impact factor: 3.257

6.  Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly.

Authors:  Tao Xie; Hailin Ding; Mingfeng Xia; Xiaobiao Zhang; Wei Sun; Tengfei Liu; Ye Gu; Chongjing Sun; Fan Hu
Journal:  Endocrine       Date:  2018-09-10       Impact factor: 3.633

7.  Health-related Quality of Life in Acromegaly Patients: Results from Generic and Disease-specific Questionnaires.

Authors:  Bruno de A Oliveira; Bruna Araújo; Tainá M Dos Santos; Bárbara R Ongaratti; Carolina G S Leães Rech; Nelson P Ferreira; Júlia F S Pereira-Lima; Miriam da C Oliveira
Journal:  Indian J Endocrinol Metab       Date:  2020-11-09

8.  Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly.

Authors:  Laura E Dichtel; Allison Kimball; Kevin C J Yuen; Whitney Woodmansee; Melanie S Haines; Qiu Xia Guan; Brooke Swearingen; Lisa B Nachtigall; Nicholas A Tritos; Julie L Sharpless; Ursula B Kaiser; Anu V Gerweck; Karen K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2020-09-11       Impact factor: 3.523

9.  Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.

Authors:  Christian J Strasburger; Niki Karavitaki; Sylvère Störmann; Peter J Trainer; Ilonka Kreitschmann-Andermahr; Michael Droste; Márta Korbonits; Berit Feldmann; Kathrin Zopf; Violet Fazal Sanderson; David Schwicker; Dana Gelbaum; Asi Haviv; Martin Bidlingmaier; Nienke R Biermasz
Journal:  Eur J Endocrinol       Date:  2015-12-18       Impact factor: 6.664

10.  Importance of Illness Acceptance Among Other Factors Affecting Quality of Life in Acromegaly.

Authors:  Aleksandra Jawiarczyk-Przybyłowska; Dorota Szcześniak; Marta Ciułkowicz; Marek Bolanowski; Joanna Rymaszewska
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.